161 related articles for article (PubMed ID: 8895542)
1. Down-regulation of tumour gelatinase/inhibitor balance and preservation of tumour endothelium by an anti-metastatic ruthenium complex.
Sava G; Capozzi I; Bergamo A; Gagliardi R; Cocchietto M; Masiero L; Onisto M; Alessio E; Mestroni G; Garbisa S
Int J Cancer; 1996 Sep; 68(1):60-6. PubMed ID: 8895542
[TBL] [Abstract][Full Text] [Related]
2. Na[trans-RuCl4(DMSO)Im], a metal complex of ruthenium with antimetastatic properties.
Sava G; Pacor S; Mestroni G; Alessio E
Clin Exp Metastasis; 1992 Jul; 10(4):273-80. PubMed ID: 1617835
[TBL] [Abstract][Full Text] [Related]
3. Reduction of in vivo lung metastases by dinuclear ruthenium complexes is coupled to inhibition of in vitro tumour invasion.
Bergamo A; Stocco G; Casarsa C; Cocchietto M; Alessio E; Serli B; Zorzet S; Sava G
Int J Oncol; 2004 Feb; 24(2):373-9. PubMed ID: 14719114
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological control of lung metastases of solid tumours by a novel ruthenium complex.
Sava G; Capozzi I; Clerici K; Gagliardi G; Alessio E; Mestroni G
Clin Exp Metastasis; 1998 May; 16(4):371-9. PubMed ID: 9626816
[TBL] [Abstract][Full Text] [Related]
5. Increase of tumour infiltrating lymphocytes in mice treated with antimetastatic doses of NAMI-A.
Magnarin M; Bergamo A; Carotenuto ME; Zorzet S; Sava G
Anticancer Res; 2000; 20(5A):2939-44. PubMed ID: 11062704
[TBL] [Abstract][Full Text] [Related]
6. Modification of cell cycle and viability of TLX5 lymphoma in vitro by sulfoxide-ruthenium compounds and cisplatin detected by flow cytometry.
Capozzi I; Clerici K; Cocchietto M; Salerno G; Bergamo A; Sava G
Chem Biol Interact; 1998 May; 113(1):51-64. PubMed ID: 9630847
[TBL] [Abstract][Full Text] [Related]
7. Altered balance between matrix metalloproteinases and their inhibitors in experimental biliary fibrosis.
Kossakowska AE; Edwards DR; Lee SS; Urbanski LS; Stabbler AL; Zhang CL; Phillips BW; Zhang Y; Urbanski SJ
Am J Pathol; 1998 Dec; 153(6):1895-902. PubMed ID: 9846979
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinases and their inhibitors.
Kugler A
Anticancer Res; 1999; 19(2C):1589-92. PubMed ID: 10365151
[TBL] [Abstract][Full Text] [Related]
9. Expression of immunoreactive matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in human normal livers and primary liver tumors.
Terada T; Okada Y; Nakanuma Y
Hepatology; 1996 Jun; 23(6):1341-4. PubMed ID: 8675149
[TBL] [Abstract][Full Text] [Related]
10. Expression of tissue inhibitor of metalloproteinase-1 and type IV collagenase/gelatinase messenger RNAs in human breast cancer.
Lindsay CK; Thorgeirsson UP; Tsuda H; Hirohashi S
Hum Pathol; 1997 Mar; 28(3):359-66. PubMed ID: 9042802
[TBL] [Abstract][Full Text] [Related]
11. Treatment of residual metastases with Na[trans-RuCl4 (DMSO)lm] and ruthenium uptake by tumor cells.
Bergamo A; Cocchietto M; Capozzi I; Mestroni G; Alessio E; Sava G
Anticancer Drugs; 1996 Aug; 7(6):697-702. PubMed ID: 8913439
[TBL] [Abstract][Full Text] [Related]
12. Reduction of lung metastasis by ImH[trans-RuCl4(DMSO)Im]: mechanism of the selective action investigated on mouse tumors.
Sava G; Clerici K; Capozzi I; Cocchietto M; Gagliardi R; Alessio E; Mestroni G; Perbellini A
Anticancer Drugs; 1999 Jan; 10(1):129-38. PubMed ID: 10194556
[TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinases and metastatic cancer.
Cockett MI; Murphy G; Birch ML; O'Connell JP; Crabbe T; Millican AT; Hart IR; Docherty AJ
Biochem Soc Symp; 1998; 63():295-313. PubMed ID: 9513731
[TBL] [Abstract][Full Text] [Related]
14. Anti-invasive activity of ursolic acid correlates with the reduced expression of matrix metalloproteinase-9 (MMP-9) in HT1080 human fibrosarcoma cells.
Cha HJ; Bae SK; Lee HY; Lee OH; Sato H; Seiki M; Park BC; Kim KW
Cancer Res; 1996 May; 56(10):2281-4. PubMed ID: 8625299
[TBL] [Abstract][Full Text] [Related]
15. Expression of gelatinases A and B, and TIMPs 1 and 2 during corneal wound healing.
Ye HQ; Azar DT
Invest Ophthalmol Vis Sci; 1998 May; 39(6):913-21. PubMed ID: 9579471
[TBL] [Abstract][Full Text] [Related]
16. Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas.
Jones JL; Glynn P; Walker RA
J Pathol; 1999 Oct; 189(2):161-8. PubMed ID: 10547569
[TBL] [Abstract][Full Text] [Related]
17. Expression of tissue inhibitor of metalloproteinases TIMP-2 in human colorectal cancer--a predictor of tumour stage.
Ring P; Johansson K; Höyhtyä M; Rubin K; Lindmark G
Br J Cancer; 1997; 76(6):805-11. PubMed ID: 9310250
[TBL] [Abstract][Full Text] [Related]
18. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN
J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545
[TBL] [Abstract][Full Text] [Related]
19. Dual Action of NAMI-A in inhibition of solid tumor metastasis: selective targeting of metastatic cells and binding to collagen.
Sava G; Zorzet S; Turrin C; Vita F; Soranzo M; Zabucchi G; Cocchietto M; Bergamo A; DiGiovine S; Pezzoni G; Sartor L; Garbisa S
Clin Cancer Res; 2003 May; 9(5):1898-905. PubMed ID: 12738748
[TBL] [Abstract][Full Text] [Related]
20. Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma.
Nuovo GJ; MacConnell PB; Simsir A; Valea F; French DL
Cancer Res; 1995 Jan; 55(2):267-75. PubMed ID: 7812956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
